Karl Freemyer

Karl Freemyer currently serves as the Head of Business Development at Herspiegel, a role assumed in October 2025, where the focus is on spearheading growth by integrating teams from Decisive Consulting, FIECON, and Herspiegel to provide comprehensive consultancy services in various sectors such as Access, health economics and outcomes research (HEOR), and commercial strategy. Prior to this, Freemyer held the position of Head of Business Development at FIECON from July 2020 to October 2025, promoting the commercialization of innovative medical technologies. Freemyer's extensive experience also includes leadership roles at Genesis Research as Senior Director, Labcorp Drug Development as Director of Business Development North America, and a commercial sales position at AstraZeneca. Freemyer began a career in market research as a Market Research Analyst at DSM Nutritional Products. Academic qualifications include an MBA in Pharmaceutical Management from Rutgers Business School and a BA in Economics from Rutgers University.